Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Measurement and predictors of adherence in a trial of HSV suppressive therapy in Tanzania.

Watson-Jones D, Baisley K, Rusizoka M, Tanton C, Mugeye K, Weiss HA, Changalucha J, Clayton T, Hambleton I, Ross DA, Hayes RJ.

Contemp Clin Trials. 2009 Nov;30(6):504-12. doi: 10.1016/j.cct.2009.07.002. Epub 2009 Aug 7.

PMID:
19665587
2.

A qualitative study of participant adherence in a randomized controlled trial of herpes suppressive therapy for HIV prevention in Tanzania.

Plummer ML, Watson-Jones D, Lees S, Baisley K, Matari S, Changalucha J, Clayton T, Mugeye K, Tanton C, Weiss HA, Ross DA, Hayes RJ.

AIDS Care. 2010 Apr;22(4):499-508. doi: 10.1080/09540120903202889.

PMID:
20140794
3.

A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.

Cowan FM, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, Hargrove JW, Robinson NJ, Bassett MT, Wilson D, Brown DW, Hayes RJ.

Sex Transm Infect. 2008 Dec;84(7):548-53. doi: 10.1136/sti.2008.031153. Epub 2008 Aug 6.

PMID:
18684855
4.

Effect of herpes simplex suppression on incidence of HIV among women in Tanzania.

Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, Tanton C, Ross D, Everett D, Clayton T, Balira R, Knight L, Hambleton I, Le Goff J, Belec L, Hayes R; HSV trial team; Steering and Data Monitoring Committees.

N Engl J Med. 2008 Apr 10;358(15):1560-71. doi: 10.1056/NEJMoa0800260. Epub 2008 Mar 12. Erratum in: N Engl J Med. 2010 Apr 15;362(15):1450.

5.

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.

Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J, Buchbinder S, Koblin B, Zwerski S, Rose S, Wang J, Corey L; HPTN 039 Protocol Team.

Lancet. 2008 Jun 21;371(9630):2109-19. doi: 10.1016/S0140-6736(08)60920-4.

6.

Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.

Tanton C, Weiss HA, Rusizoka M, Legoff J, Changalucha J, Baisley K, Mugeye K, Everett D, Belec L, Clayton TC, Ross DA, Hayes RJ, Watson-Jones D.

J Infect Dis. 2010 May 1;201(9):1285-97. doi: 10.1086/651696.

7.

Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania.

Tanton C, Weiss HA, LeGoff J, Changalucha J, Clayton TC, Ross DA, Belec L, Hayes RJ, Watson-Jones D.

Sex Transm Infect. 2011 Aug;87(5):406-11. doi: 10.1136/sti.2010.048496. Epub 2011 Jun 8.

8.

Risk factors for HIV incidence in women participating in an HSV suppressive treatment trial in Tanzania.

Watson-Jones D, Baisley K, Weiss HA, Tanton C, Changalucha J, Everett D, Chirwa T, Ross D, Clayton T, Hayes R.

AIDS. 2009 Jan 28;23(3):415-22. doi: 10.1097/QAD.0b013e32831ef523.

9.

A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial.

Jacob ST, Baeten JM, Hughes JP, Peinado J, Wang J, Sanchez J, Reid SE, Delany-Moretlwe S, Cowan F, Fuchs JD, Koblin B, Griffith S, Wald A, Celum C.

AIDS Behav. 2011 Jul;15(5):897-904. doi: 10.1007/s10461-010-9853-2.

10.

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins JI, Hughes JP, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell MS, Thomas KK, Coombs RW, Morrow R, Whittington WL, McElrath MJ, Barnes L, Ridzon R, Corey L; Partners in Prevention HSV/HIV Transmission Study Team.

N Engl J Med. 2010 Feb 4;362(5):427-39. doi: 10.1056/NEJMoa0904849. Epub 2010 Jan 20.

11.

Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.

Mayaud P, Legoff J, Weiss HA, Grésenguet G, Nzambi K, Bouhlal H, Frost E, Pépin J, Malkin JE, Hayes RJ, Mabey DC, Bélec L; ANRS 1212 Study Group.

J Infect Dis. 2009 Jul 15;200(2):216-26. doi: 10.1086/599991.

PMID:
19530940
12.

High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.

Perti T, Saracino M, Baeten JM, Johnston C, Diem K, Ocbamichael N, Huang ML, Selke S, Magaret A, Corey L, Wald A.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):201-8. doi: 10.1097/QAI.0b013e3182928eea.

13.

Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial.

Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Nakku-Joloba E, Mirembe F.

Reprod Health. 2017 Mar 3;14(1):31. doi: 10.1186/s12978-017-0292-7.

14.

Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherence.

Donnell DJ, Baeten JM, Hong T, Lingappa JR, Mujugira A, Nakku-Joloba E, Bangsberg D, Celum C.

AIDS Behav. 2013 Feb;17(2):632-9. doi: 10.1007/s10461-012-0268-0.

15.

The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.

Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G.

Sex Transm Dis. 2011 May;38(5):401-9. doi: 10.1097/OLQ.0b013e31820b8bc8.

PMID:
21317689
16.

Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART: a pilot randomized controlled trial.

Nijhawan AE, Delong AK, Chapman S, Rana A, Kurpewski J, Ingersoll J, Caliendo AM, Cu-Uvin S.

Infect Dis Obstet Gynecol. 2012;2012:868526. doi: 10.1155/2012/868526. Epub 2012 Feb 28.

17.

Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.

Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, Foulongne V, Sanon A, Andonaba JB, Segondy M, Mayaud P, Van de Perre P.

AIDS. 2006 Nov 28;20(18):2305-13.

PMID:
17117016
18.

High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.

Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C.

J Infect Dis. 2011 Dec 15;204(12):1912-7. doi: 10.1093/infdis/jir649. Epub 2011 Oct 12.

19.

Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial.

Paz-Bailey G, Sternberg M, Puren AJ, Markowitz LE, Ballard R, Delany S, Hawkes S, Nwanyanwu O, Ryan C, Lewis DA.

J Infect Dis. 2009 Oct 1;200(7):1039-49. doi: 10.1086/605647.

PMID:
19715417
20.

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret AS, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

Lancet. 2010 Mar 6;375(9717):824-33. doi: 10.1016/S0140-6736(09)62038-9. Epub 2010 Feb 12.

Supplemental Content

Support Center